Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus

Lupus

Volumn 8, Issue 2, 1999, Pages 103-108

  Tjernstrom F ^a   Hellmer, G ^a   Nived, O ^a   Truedsson, L ^a   Sturfelt, G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Genetics; IL 1RA; MHC; Microsatellite; SLE

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; CHROMOSOME 2; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOASSAY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032929825     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847560     Document Type: Article

References (26)

1. Dayer J-M, Arend WP. Cytokines and growth factors. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds). Textbook of Rheumatology. WB Saunders: Philadelphia, 1997, pp 267-286.
2. Weckmann AL, Alcocer-Varela J. Cytokine inhibitors in autoimmune disease. Sem Arthritis Rheum 1996; 26: 539-557.
3. Tarlow JK et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by a variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-404.
4. Blakemore AIF et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996; 97: 369-374.
5. Mansfield JC et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106: 637-642.
6. Bioque G et al. Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8: 105-110.
7. Clay FE et al. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet 1996; 97: 723-726.
8. Truedsson L et al. Sharing of MHC haplotypes among patients with Systemic Lupus Erythematosus from unrelated Caucasian multicase families: disease association with the extended haplotype [HLA-B8,SC01,DR17]. J Rheumatol 1995; 22: 1852-1861.
9. Mehrian R et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998; 41: 596-602.
10. Sturfelt G, Roux-Lombard O, Wollheim FA, Dayer J-M. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in Systemic Lupus Erythematosus. Br J Rheumatol 1997; 36: 1283-1289.
11. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active Systemic Lupus Erythematosus. Arthritis Rheum 1995; 38: 1055-1059.
12. Hsieh S-C et al. Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by Polymorphonuclear neutrophils of patients with active Systemic Lupus Erythematosus. Br J Rheumatol 1995; 34: 107-112.
13. Blakemore AIF et al. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in Systemic Lupus Erythematosus. Arthritis Rheum 1994; 37: 1380-1385.
14. Danis VA, Millington M, Hyland VJ, Grennani D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (JL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-310.
15. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA Allele 2 (IL1RN*2) is associated with enhanced IL-1β production in vitro. Scand J Immunol 1998; 47: 195-198.
16. Jonsson H, Nived O, Sturfelt G, Outcome in Systemic Lupus erythematosus: A prospective study of patients from a defined population. Medicine 1989; 68: 141-150.
17. Tan EL et al. The 1982 revised criteria for the classification of Systemic Lupus Erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
18. Gladman D et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for Systemic Lupus Erythemalosus. Arthritis Rheum 1996; 39: 363-369.
19. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, 2nd edn. Cold Spring Harbor Laboratory: New York, 1989, pp 9.16-9.19.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16: 1215-1225.
21. Olerup O. Zetterquist H. HLA-DR typing in PCR amplification with sequence-spccific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
22. Olerup O, Zetterquist H. DR 'low resolution' PCR-SSP typing - a correction and an up-date. Tissue Antigens 1993; 41: 55-56.
23. Aldener-Cannavá A, Olerup O. HLA-DQB1 'low-resolution' typing by PCR amplification with sequence-specific primers (PCR-SSP). Eur J Immunogenetics 1994; 21: 447-455.
24. Bombardier C et al. Derivation of the SLHDAI. Arthritis Rheum 1992; 35: 630-640.
25. Winchester R. Genetic susceptibility to Systemic Lupus Erythematosus. In: Lahita RG (ed). Systemic Lupus Erythematosus. Churchill Livingstone: New York, 1991, pp 65-85.
26. Lewkonia RM. The clinical genetics of Lupus. Lupus 1992; 1: 55-62.